Philip Rye

Company: AlgiPharma AS

Job title: Chief Scientific Officer

Seminars:

Potential Concerns with Repeat Doses of Lipid Nanoparticle Drug Products for Chronic Lung Diseases 12:00 pm

Spotlighting the role lipid nanoparticles can play in the treatment of chronic diseases Addressing the industry concerns when administering lipid nanoparticles to limit accumulation Quantifying the fluctuations in endosomal release efficiency throughout timeRead more

day: Conference day One